University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Dolores Shoback, M.D.

Endocrinologist

Dr. Dolores Shoback sees general endocrine patients with an emphasis on metabolic bone disease, parathyroid disorders and osteoporosis. She is board certified in internal medicine with a subspecialty in endocrinology and metabolism. A professor of medicine and director of the UCSF Training Program in Diabetes, Endocrinology and Metabolism, her research interests are metabolic bone disease, the calcium sensing receptor and parathyroid hormone. Shoback completed her undergraduate studies at the University of Pennsylvania. She went on to Johns Hopkins University for medical school and performed a residency in internal medicine at Johns Hopkins Hospital and then completed a fellowship in endocrinology at Brigham and Woman's Hospital in Boston.

Clinics

Endocrinology Clinic at Parnassus
400 Parnassus Ave., Suite A-550
San Francisco, CA 94143
Phone: (415) 353–2350
Fax: (415) 353–2337

Hours: Monday to Friday, 8:30 a.m. – 5 pm.

Conditions & Treatments

More about Dolores Shoback

Education

Johns Hopkins School of Medicine 1977

Residencies

Johns Hopkins Hospital, Internal Medicine 1980

Fellowships

Brigham and Woman's Hospital, Endocrinology 1983

Selected Research and Publications

  1. Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015 Aug; 173(2):G1-G20.
  2. Shah AD, Shoback D, Lewiecki EM. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. Int J Womens Health. 2015; 7:565-80.
  3. Schafer AL, Li X, Schwartz AV, Tufts LS, Wheeler AL, Grunfeld C, Stewart L, Rogers SJ, Carter JT, Posselt AM, Black DM, Shoback DM. Changes in vertebral bone marrow fat and bone mass after gastric bypass surgery: A pilot study. Bone. 2015 May; 74:140-5.
  4. Lai JC, Shoback DM, Zipperstein J, Lizaola B, Tseng S, Terrault NA. Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci. 2015 Jan 7.
  5. Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab. 2014 Oct; 99(10):3607-18.
  6. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014 Oct; 99(10):3570-9.
  7. Schafer AL, Mumm S, El-Sayed I, McAlister WH, Horvai AE, Tom AM, Hsiao EC, Schaefer FV, Collins MT, Anderson MS, Whyte MP, Shoback DM. Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK. J Bone Miner Res. 2014 Apr; 29(4):911-21.
  8. Canales BK, Schafer AL, Shoback DM, Carpenter TO. Gastric bypass in obese rats causes bone loss, vitamin D deficiency, metabolic acidosis, and elevated peptide YY. Surg Obes Relat Dis. 2014 Sep-Oct; 10(5):878-84.
  9. Hong SH, Dvorak-Ewell M, Stevens HY, Barish GD, Castro GL, Nofsinger R, Frangos JA, Shoback D, Evans RM. Rescue of a primary myelofibrosis model by retinoid-antagonist therapy. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):18820-5.
  10. Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013 Dec; 1(4):275-83.
  11. Cheng Z, Liang N, Chen TH, Li A, Santa Maria C, You M, Ho H, Song F, Bikle D, Tu C, Shoback D, Chang W. Sex and age modify biochemical and skeletal manifestations of chronic hyperparathyroidism by altering target organ responses to Ca2+ and parathyroid hormone in mice. J Bone Miner Res. 2013 May; 28(5):1087-100.
  12. Schafer AL, Burghardt AJ, Sellmeyer DE, Palermo L, Shoback DM, Majumdar S, Black DM. Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS). Osteoporos Int. 2013 Oct; 24(10):2591-601.
  13. Nemeth EF, Shoback D. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. Best Pract Res Clin Endocrinol Metab. 2013 Jun; 27(3):373-84.
  14. Park-Sigal J, Don BR, Porzig A, Recker R, Griswold V, Sebastian A, Duh QY, Portale AA, Shoback D, Schambelan M. Severe hypercalcemic hyperparathyroidism developing in a patient with hyperaldosteronism and renal resistance to parathyroid hormone. J Bone Miner Res. 2013 Mar; 28(3):700-8.
  15. Schafer AL, Sellmeyer DE, Palermo L, Hietpas J, Eastell R, Shoback DM, Black DM. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial. J Clin Endocrinol Metab. 2012 Oct; 97(10):3522-9.
  16. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012 Jul; 97(7):2272-82.
  17. Dvorak-Ewell MM, Chen TH, Liang N, Garvey C, Liu B, Tu C, Chang W, Bikle DD, Shoback DM. Osteoblast extracellular Ca2+ -sensing receptor regulates bone development, mineralization, and turnover. J Bone Miner Res. 2011 Dec; 26(12):2935-47.
  18. Prasad AP, George V, Porzig A, Horvai AE, Gross A, Shoback D, Link TM. Progressive craniofacial bone loss after cosmetic surgery at the forehead. Skeletal Radiol. 2012 Apr; 41(4):477-81.
  19. Schafer AL, Sellmeyer DE, Schwartz AV, Rosen CJ, Vittinghoff E, Palermo L, Bilezikian JP, Shoback DM, Black DM. Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab. 2011 Dec; 96(12):E1982-9.
  20. Bilezikian JP, Khan A, Potts JT, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011 Oct; 26(10):2317-37.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.